Kathy Chi‐Burris

1.2k total citations · 1 hit paper
9 papers, 677 citations indexed

About

Kathy Chi‐Burris is a scholar working on Psychiatry and Mental health, Neurology and Pediatrics, Perinatology and Child Health. According to data from OpenAlex, Kathy Chi‐Burris has authored 9 papers receiving a total of 677 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Psychiatry and Mental health, 5 papers in Neurology and 2 papers in Pediatrics, Perinatology and Child Health. Recurrent topics in Kathy Chi‐Burris's work include Parkinson's Disease Mechanisms and Treatments (5 papers), Attention Deficit Hyperactivity Disorder (5 papers) and Bipolar Disorder and Treatment (2 papers). Kathy Chi‐Burris is often cited by papers focused on Parkinson's Disease Mechanisms and Treatments (5 papers), Attention Deficit Hyperactivity Disorder (5 papers) and Bipolar Disorder and Treatment (2 papers). Kathy Chi‐Burris collaborates with scholars based in United States, United Kingdom and Portugal. Kathy Chi‐Burris's co-authors include Stuart Isaacson, Roger Mills, Clive Ballard, Hilde Williams, Rohit Dhall, Anne Corbett, Jeffrey L. Cummings, Jack M. Gwaltney, Frederick G. Hayden and Ronald B. Turner and has published in prestigious journals such as The Lancet, Antimicrobial Agents and Chemotherapy and Journal of the Neurological Sciences.

In The Last Decade

Kathy Chi‐Burris

9 papers receiving 640 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Pimavanserin for patients with Parkinson's disease psychosis: a randomised, placebo-controlled phase 3 trial

2013 481 citations Jeffrey L. Cummings, Stuart Isaacson et al. The Lancet profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Kathy Chi‐Burris United States	5	332	161	145	89	76	9	677
David Stamler United States	17	365 1.1×	214 1.3×	221 1.5×	45 0.5×	75 1.0×	46	952
José Rocha Portugal	14	183 0.6×	332 2.1×	158 1.1×	27 0.3×	47 0.6×	48	644
Rani K. Singh United States	12	72 0.2×	376 2.3×	121 0.8×	35 0.4×	68 0.9×	32	556
Linda Mancione United States	8	133 0.4×	215 1.3×	38 0.3×	19 0.2×	73 1.0×	12	483
Matthew J. Lennon Australia	10	64 0.2×	134 0.8×	40 0.3×	58 0.7×	33 0.4×	23	611
Andrew Dougherty United States	5	153 0.5×	63 0.4×	53 0.4×	45 0.5×	28 0.4×	8	387
Coleen Hall United States	11	434 1.3×	58 0.4×	79 0.5×	483 5.4×	47 0.6×	18	927
C. Frenkel Germany	14	78 0.2×	45 0.3×	196 1.4×	53 0.6×	19 0.3×	33	590
Noeline Latt Australia	8	160 0.5×	51 0.3×	97 0.7×	243 2.7×	46 0.6×	10	538
Fei Cao China	10	53 0.2×	212 1.3×	23 0.2×	111 1.2×	70 0.9×	21	636

Countries citing papers authored by Kathy Chi‐Burris

Since Specialization

Citations

This map shows the geographic impact of Kathy Chi‐Burris's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kathy Chi‐Burris with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kathy Chi‐Burris more than expected).

Fields of papers citing papers by Kathy Chi‐Burris

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kathy Chi‐Burris. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kathy Chi‐Burris. The network helps show where Kathy Chi‐Burris may publish in the future.

Co-authorship network of co-authors of Kathy Chi‐Burris

This figure shows the co-authorship network connecting the top 25 collaborators of Kathy Chi‐Burris. A scholar is included among the top collaborators of Kathy Chi‐Burris based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kathy Chi‐Burris. Kathy Chi‐Burris is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

9 of 9 papers shown

Citrome, Leslie, James Norton, Kathy Chi‐Burris, & George D. Demos. (2018). 152 Pimavanserin for the Treatment of Parkinson’s Disease Psychosis: Number Needed to Treat, Number Needed to Harm, and Likelihood to Be Helped or Harmed. CNS Spectrums. 23(1). 94–95. 1 indexed citations

Citrome, Leslie, James C. Norton, Kathy Chi‐Burris, & George Demos. (2017). Pimavanserin for the treatment of Parkinson’s disease psychosis: number needed to treat, number needed to harm, and likelihood to be helped or harmed. CNS Spectrums. 23(3). 228–238. 12 indexed citations

Mills, Roger, Stuart Isaacson, Joaquim J. Ferreira, et al.. (2015). Long-term effectiveness of NUPLAZID™ (pimavanserin) in PD psychosis: Data from 2 open-label studies. Parkinsonism & Related Disorders. 22. e92–e93. 6 indexed citations

Mills, Roger, Joseph H. Friedman, William G. Ondo, et al.. (2015). Efficacy and tolerability of NUPLAZID™ (pimavanserin) in PD Psychosis: Analysis of an integrated Phase 3 placebo-controlled dataset. Parkinsonism & Related Disorders. 22. e92–e92. 2 indexed citations

Mills, Roger, Stuart Isaacson, Joaquim Ferreira, et al.. (2015). Long-term effectiveness of NUPLAZID™ (pimavanserin) in PD psychosis: Data from 2 open-label studies. Parkinsonism & Related Disorders. 22. e28–e28. 3 indexed citations

Cummings, Jeffrey L., Stuart Isaacson, Roger Mills, et al.. (2013). Pimavanserin for patients with Parkinson's disease psychosis: a randomised, placebo-controlled phase 3 trial. The Lancet. 383(9916). 533–540. 481 indexed citations breakdown →

Cummings, Joanne, Stuart Isaacson, Roger Mills, et al.. (2013). Antipsychotic efficacy and motor tolerability in a phase III placebo-controlled study of pimavanserin in patients with Parkinson's Disease psychosis (Acp-103-020). Journal of the Neurological Sciences. 333. e119–e120. 12 indexed citations

Ballard, Clive, Roger Mills, Hilde Williams, et al.. (2013). O4–05–04: Antipsychotic efficacy and good tolerability in a Phase III placebo‐controlled study of pimavanserin in patients with Parkinson's disease psychosis (ACP‐103–020). Alzheimer s & Dementia. 9(4S_Part_17). 1 indexed citations

Hayden, Frederick G., Ronald B. Turner, Jack M. Gwaltney, et al.. (2003). Phase II, Randomized, Double-Blind, Placebo-Controlled Studies of Ruprintrivir Nasal Spray 2-Percent Suspension for Prevention and Treatment of Experimentally Induced Rhinovirus Colds in Healthy Volunteers. Antimicrobial Agents and Chemotherapy. 47(12). 3907–3916. 159 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact